carbamates has been researched along with Headache in 17 studies
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The most common adverse events were upper respiratory tract infection (36 [10%] patients) and headache (18 [5%] patients)." | 6.90 | Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. ( Brainard, DM; Cheng, J; Dao, L; Dou, X; Duan, Z; Dvory-Sobol, H; Gao, Y; Gao, ZL; Gong, G; Hou, JL; Hu, P; Huang, Y; Jia, J; Le Manh, H; Le, TTP; Li, J; Lim, SG; Lin, F; Lu, S; Mao, Y; Mo, H; Mohamed, R; Mou, Z; Nan, Y; Ning, Q; Piratvisuth, T; Shang, J; Sobhonslidsuk, A; Stamm, LM; Su, M; Tan, CK; Tang, H; Tangkijvanich, P; Tanwandee, T; Tee, HP; Thongsawat, S; Văn, KN; Wang, GQ; Wei, L; Wu, S; Xie, Q; Xu, M; Yang, YF; Zhang, L, 2019) |
| "Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg-IFN) and ribavirin (RBV) have limited therapeutic options." | 5.16 | Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. ( Chayama, K; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Takahashi, S; Toyota, J; Watanabe, H, 2012) |
| "A literature search through EMBASE and PubMed was conducted (January 1966 to August 2015) using the terms BMS-790052, daclatasvir, and hepatitis C." | 4.93 | Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection. ( Mohammad, RA; Regal, RE; Smith, MA, 2016) |
| "The most common adverse events were upper respiratory tract infection (36 [10%] patients) and headache (18 [5%] patients)." | 2.90 | Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. ( Brainard, DM; Cheng, J; Dao, L; Dou, X; Duan, Z; Dvory-Sobol, H; Gao, Y; Gao, ZL; Gong, G; Hou, JL; Hu, P; Huang, Y; Jia, J; Le Manh, H; Le, TTP; Li, J; Lim, SG; Lin, F; Lu, S; Mao, Y; Mo, H; Mohamed, R; Mou, Z; Nan, Y; Ning, Q; Piratvisuth, T; Shang, J; Sobhonslidsuk, A; Stamm, LM; Su, M; Tan, CK; Tang, H; Tangkijvanich, P; Tanwandee, T; Tee, HP; Thongsawat, S; Văn, KN; Wang, GQ; Wei, L; Wu, S; Xie, Q; Xu, M; Yang, YF; Zhang, L, 2019) |
| " However, information about the rate of adverse events (AEs) across different DAA regimens is limited." | 2.87 | Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study. ( Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N, 2018) |
| " XP13512 immediate-release (up to 2800 mg single dose and 2100 mg twice daily) was well absorbed (>68%, based on urinary recovery of gabapentin), converted rapidly to gabapentin, and provided dose-proportional exposure, whereas absorption of oral gabapentin declined with increasing doses to <27% at 1200 mg." | 2.73 | Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. ( Canafax, DM; Cundy, KC; Luo, W; Moors, TL; Sastry, S; Zou, J, 2008) |
| "Brecanavir (BCV, 640385) is a novel, potent protease inhibitor (PI) with low nanomolar 50% inhibitory concentrations against PI-resistant human immunodeficiency virus (HIV) in vitro." | 2.72 | Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. ( Anderson, MT; Fernandez, P; Ford, SL; Johnson, MA; Murray, SC; Reddy, YS; Stein, DS, 2006) |
| " Cenobamate demonstrated significant efficacy at a dosage between 100 and 400 mg per day." | 2.66 | Cenobamate for the treatment of focal epilepsies. ( Bauer, S; Mann, C; Rosenow, F; Strzelczyk, A; Willems, LM, 2020) |
| " Pharmacokinetic sampling was conducted on the last day of each treatment." | 1.33 | Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. ( Borland, J; Ford, SL; Lou, Y; Min, SS; Shelton, MJ; Wire, MB; Xue, ZG; Yuen, G, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Cursino, CN | 1 |
| Monteiro, PGO | 1 |
| Duarte, GDS | 1 |
| Vieira, TBQ | 1 |
| Crisante, VC | 1 |
| Giordani, F | 1 |
| Xavier, AR | 1 |
| de Almeida, RMVR | 1 |
| Calil-Elias, S | 1 |
| Strzelczyk, A | 1 |
| Mann, C | 1 |
| Willems, LM | 1 |
| Rosenow, F | 1 |
| Bauer, S | 1 |
| Sølund, C | 1 |
| Andersen, ES | 1 |
| Mössner, B | 1 |
| Laursen, AL | 1 |
| Røge, BT | 1 |
| Kjær, MS | 1 |
| Gerstoft, J | 1 |
| Christensen, PB | 1 |
| Pedersen, MS | 1 |
| Schønning, K | 1 |
| Fahnøe, U | 1 |
| Bukh, J | 1 |
| Weis, N | 1 |
| Wei, L | 1 |
| Lim, SG | 1 |
| Xie, Q | 1 |
| Văn, KN | 1 |
| Piratvisuth, T | 1 |
| Huang, Y | 1 |
| Wu, S | 1 |
| Xu, M | 1 |
| Tang, H | 1 |
| Cheng, J | 1 |
| Le Manh, H | 1 |
| Gao, Y | 1 |
| Mou, Z | 1 |
| Sobhonslidsuk, A | 1 |
| Dou, X | 1 |
| Thongsawat, S | 1 |
| Nan, Y | 1 |
| Tan, CK | 1 |
| Ning, Q | 1 |
| Tee, HP | 1 |
| Mao, Y | 1 |
| Stamm, LM | 1 |
| Lu, S | 1 |
| Dvory-Sobol, H | 1 |
| Mo, H | 1 |
| Brainard, DM | 1 |
| Yang, YF | 1 |
| Dao, L | 1 |
| Wang, GQ | 1 |
| Tanwandee, T | 1 |
| Hu, P | 1 |
| Tangkijvanich, P | 1 |
| Zhang, L | 1 |
| Gao, ZL | 1 |
| Lin, F | 1 |
| Le, TTP | 1 |
| Shang, J | 1 |
| Gong, G | 1 |
| Li, J | 2 |
| Su, M | 1 |
| Duan, Z | 1 |
| Mohamed, R | 1 |
| Hou, JL | 1 |
| Jia, J | 1 |
| Sax, PE | 1 |
| Wohl, D | 1 |
| Yin, MT | 1 |
| Post, F | 1 |
| DeJesus, E | 1 |
| Saag, M | 1 |
| Pozniak, A | 1 |
| Thompson, M | 1 |
| Podzamczer, D | 1 |
| Molina, JM | 1 |
| Oka, S | 1 |
| Koenig, E | 1 |
| Trottier, B | 1 |
| Andrade-Villanueva, J | 1 |
| Crofoot, G | 1 |
| Custodio, JM | 1 |
| Plummer, A | 1 |
| Zhong, L | 1 |
| Cao, H | 1 |
| Martin, H | 1 |
| Callebaut, C | 1 |
| Cheng, AK | 1 |
| Fordyce, MW | 1 |
| McCallister, S | 1 |
| Zeuzem, S | 1 |
| Ghalib, R | 1 |
| Reddy, KR | 1 |
| Pockros, PJ | 1 |
| Ben Ari, Z | 1 |
| Zhao, Y | 1 |
| Brown, DD | 1 |
| Wan, S | 1 |
| DiNubile, MJ | 1 |
| Nguyen, BY | 1 |
| Robertson, MN | 1 |
| Wahl, J | 1 |
| Barr, E | 1 |
| Butterton, JR | 1 |
| Smith, MA | 1 |
| Regal, RE | 1 |
| Mohammad, RA | 1 |
| Tongpoo, A | 1 |
| Sriapha, C | 1 |
| Wongvisawakorn, S | 1 |
| Rittilert, P | 1 |
| Trakulsrichai, S | 1 |
| Wananukul, W | 1 |
| Yao, Y | 1 |
| Yue, M | 1 |
| Wang, J | 1 |
| Chen, H | 1 |
| Liu, M | 1 |
| Zang, F | 1 |
| Zhang, Y | 1 |
| Huang, P | 1 |
| Yu, R | 1 |
| Cundy, KC | 1 |
| Sastry, S | 1 |
| Luo, W | 1 |
| Zou, J | 1 |
| Moors, TL | 1 |
| Canafax, DM | 1 |
| Chayama, K | 1 |
| Takahashi, S | 1 |
| Toyota, J | 1 |
| Karino, Y | 1 |
| Ikeda, K | 1 |
| Ishikawa, H | 1 |
| Watanabe, H | 1 |
| McPhee, F | 1 |
| Hughes, E | 1 |
| Kumada, H | 1 |
| Gil-Nagel, A | 1 |
| Brodie, MJ | 1 |
| Leroy, R | 1 |
| Cyr, T | 1 |
| Hall, S | 1 |
| Castiglia, M | 1 |
| Twomey, C | 1 |
| VanLandingham, K | 1 |
| BRAM, G | 1 |
| ABRUZZI, WA | 1 |
| Shelton, MJ | 1 |
| Ford, SL | 2 |
| Borland, J | 1 |
| Lou, Y | 1 |
| Wire, MB | 1 |
| Min, SS | 1 |
| Xue, ZG | 1 |
| Yuen, G | 1 |
| Reddy, YS | 1 |
| Anderson, MT | 1 |
| Murray, SC | 1 |
| Fernandez, P | 1 |
| Stein, DS | 1 |
| Johnson, MA | 1 |
| Guillet, P | 1 |
| N'Guessan, R | 1 |
| Darriet, F | 1 |
| Traore-Lamizana, M | 1 |
| Chandre, F | 1 |
| Carnevale, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV[NCT02671500] | Phase 3 | 375 participants (Actual) | Interventional | 2016-04-19 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Trea[NCT01780506] | Phase 3 | 872 participants (Actual) | Interventional | 2012-12-26 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treat[NCT01797445] | Phase 3 | 872 participants (Actual) | Interventional | 2013-03-12 | Completed | ||
| Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994] | 275 participants (Actual) | Observational [Patient Registry] | 2018-02-06 | Active, not recruiting | |||
| Open-Labeled Trial Of Direct-Acting Antiviral Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors[NCT02743897] | Phase 1/Phase 2 | 62 participants (Actual) | Interventional | 2016-05-01 | Completed | ||
| A Prospective Cohort Study to Improve HCV Care Using Multidisciplinary Approach to the Treatment of Chronic Hepatitis C in Dialysis Patients: The MATCH-D Study[NCT03791814] | Phase 4 | 0 participants (Actual) | Interventional | 2019-01-01 | Withdrawn (stopped due to The study was stopped due to difficulty in identifying potential patients.) | ||
| An Open-label, Cohort Study of Grazoprevir/Elbasvir Combination Therapy for Patients With Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation[NCT03723824] | Phase 4 | 14 participants (Actual) | Interventional | 2019-02-14 | Terminated (stopped due to COV-19 pandemic) | ||
| Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors[NCT03146741] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2017-05-16 | Completed | ||
| Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney[NCT03296930] | Phase 4 | 100 participants (Anticipated) | Interventional | 2017-10-01 | Not yet recruiting | ||
| A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection.[NCT02105467] | Phase 3 | 421 participants (Actual) | Interventional | 2014-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02671500)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| SOF/VEL | 0 |
Virologic failure was defined as: (1) On-treatment virologic failure: Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while on treatment), or rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) or (2) Virologic relapse: confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at last on-treatment visit. (NCT02671500)
Timeframe: Up to Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 3.2 |
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment. (NCT02671500)
Timeframe: Posttreatment Week 12
| Intervention | Percentage of participants (Number) |
|---|---|
| SOF/VEL (Overall) | 96.5 |
| SOF/VEL (China - Region 1) | 96.2 |
| SOF/VEL (Southeast Asia - Region 2) | 97.3 |
SVR 24 was defined as HCV RNA < LLOQ at 24 weeks after stopping study treatment. (NCT02671500)
Timeframe: Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 96.5 |
SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping study treatment. (NCT02671500)
Timeframe: Posttreatment Week 4
| Intervention | Percentage of participants (Number) |
|---|---|
| SOF/VEL | 97.1 |
(NCT02671500)
Timeframe: Baseline and up to Week 12
| Intervention | log10 IU/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Change at Week 1 | Change at Week 2 | Change at Week 4 | Change at Week 6 | Change at Week 8 | Change at Week 10 | Change at Week 12 | |
| SOF/VEL | -4.38 | -4.89 | -5.02 | -5.03 | -5.03 | -5.03 | -5.03 |
(NCT02671500)
Timeframe: Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | |
| SOF/VEL | 27.7 | 73.8 | 95.5 | 99.7 | 100.0 | 100.0 | 100.0 |
(NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 323 |
| E/C/F/TDF | 310 |
(NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 235 |
| E/C/F/TDF | 221 |
(NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 285 |
| E/C/F/TDF | 271 |
(NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.04 |
| E/C/F/TDF | 0.08 |
(NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.08 |
| E/C/F/TDF | 0.11 |
(NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.05 |
| E/C/F/TDF | 0.07 |
Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.826 |
| E/C/F/TDF | -3.475 |
Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.951 |
| E/C/F/TDF | -3.515 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.865 |
| E/C/F/TDF | -3.200 |
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.809 |
| E/C/F/TDF | -3.023 |
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -1.337 |
| E/C/F/TDF | -2.956 |
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.907 |
| E/C/F/TDF | -3.053 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -24.6 |
| E/C/F/TDF | 60.4 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -32.8 |
| E/C/F/TDF | 18.0 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -33.5 |
| E/C/F/TDF | 32.5 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 37.4 |
| E/C/F/TDF | 106.9 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 11.3 |
| E/C/F/TDF | 75.0 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 6.9 |
| E/C/F/TDF | 51.2 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 93.1 |
| E/C/F/TDF | 92.8 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 144 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 31.3 | 6.0 | 0.2 |
| E/C/F/TDF | 37.1 | 7.0 | 0.2 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 48 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 25.8 | 4.6 | 0 |
| E/C/F/TDF | 32.3 | 4.9 | 0.2 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 96 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 28.8 | 5.1 | 0.2 |
| E/C/F/TDF | 33.9 | 5.8 | 0.2 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 48, 96. and 144
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 48 | Week 96 | Week 144 | |
| E/C/F/TAF | 86.4 | 84.4 | 84.6 |
| E/C/F/TDF | 87.3 | 83.6 | 80.1 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 96 and 144
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 96 | Week 144 | |
| E/C/F/TAF | 89.2 | 86.9 |
| E/C/F/TDF | 88.2 | 83.1 |
(NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 225 |
| E/C/F/TDF | 200 |
(NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 274 |
| E/C/F/TDF | 260 |
(NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.08 |
| E/C/F/TDF | 0.12 |
(NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.04 |
| E/C/F/TDF | 0.07 |
Hip BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.364 |
| E/C/F/TDF | -3.023 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.420 |
| E/C/F/TDF | -2.603 |
Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -1.278 |
| E/C/F/TDF | -2.759 |
Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -1.017 |
| E/C/F/TDF | -2.516 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -29.3 |
| E/C/F/TDF | 32.3 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -31.0 |
| E/C/F/TDF | 35.2 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 16.9 |
| E/C/F/TDF | 73.7 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 13.3 |
| E/C/F/TDF | 51.7 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 91.6 |
| E/C/F/TDF | 88.5 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 84.0 |
| E/C/F/TDF | 82.3 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| E/C/F/TAF | 82.4 | 78.7 |
| E/C/F/TDF | 80.7 | 76.8 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 48
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 27.3 | 4.7 | 0 |
| E/C/F/TDF | 31.6 | 4.6 | 0 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 96
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 31.8 | 5.4 | 0 |
| E/C/F/TDF | 36.9 | 5.1 | 0 |
Subjects with post-treatment sustained virologic response (SVR) = Number of subjects with negative HCV RNA 12 weeks after completing therapy / number of subjects treated post-kidney transplantation (NCT02743897)
Timeframe: Baseline to 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Direct-acting Antiviral Treatment for HCV | 62 |
Number of subjects with major adverse events attributable to HCV therapy in post-kidney transplant (NCT02743897)
Timeframe: Baseline to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Direct-acting Antiviral Treatment for HCV | 1 |
The primary analysis will be based on a calculation of SVR rates (number of subjects with SVR; negative HCV RNA after completing Zepatier therapy) / (number of subjects treated with Zepatier post-heart transplantation) (NCT03146741)
Timeframe: Baseline to 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Zepatier (Grazoprevir 100mg and Elbasvir 50 mg) | 9 |
(NCT03146741)
Timeframe: Baseline to 52 weeks
| Intervention | Severe adverse event (Number) |
|---|---|
| Zepatier (Grazoprevir 100mg and Elbasvir 50 mg) | 0 |
Hepatitis C Virus (HCV) ribonucleic acid (RNA) was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR12 was defined as HCV RNA
Timeframe: Week 24 (12 weeks after the end of treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment Group | 94.6 |
Hepatitis C Virus RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR24 was defined as HCV RNA
Timeframe: Week 36 (24 weeks after the end of treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment Group | 94.3 |
Hepatitis C Virus RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay. SVR4 was defined as HCV RNA
Timeframe: Week 16 (4 weeks after the end of treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment Group | 97.2 |
An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. (NCT02105467)
Timeframe: Up to Week 12 (end of Blinded Treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment Group | 0.9 |
| Deferred Treatment Group | 1.0 |
An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. (NCT02105467)
Timeframe: Up to Week 14 (14 days after the Blinded Treatment was completed)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment Group | 67.4 |
| Deferred Treatment Group | 68.6 |
2 reviews available for carbamates and Headache
| Article | Year |
|---|---|
Cenobamate for the treatment of focal epilepsies.
Topics: Animals; Anticonvulsants; Carbamates; Chlorophenols; Epilepsies, Partial; Headache; Humans; Randomiz | 2020 |
Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Headache; Hepacivirus; Hepatitis | 2016 |
8 trials available for carbamates and Headache
7 other studies available for carbamates and Headache
| Article | Year |
|---|---|
Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Brazil; Carbamates; Drug Therapy, Combinat | 2019 |
OCCUPATIONAL CARBAMATE POISONING IN THAILAND.
Topics: Adolescent; Adult; Aged; Agricultural Workers' Diseases; Carbamates; Carbofuran; Child; Diarrhea; Fe | 2015 |
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
Topics: Amides; Antiviral Agents; Asthenia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combinatio | 2017 |
[Clinical and double blind trials with MH 532 (Gamaquil) in tension headache].
Topics: Carbamates; Cardiovascular Agents; Double-Blind Method; Headache; Muscle Relaxants, Central; Tension | 1962 |
A CONTROLLED EVALUATION OF CHLORPHENESIN CARBAMATE IN PAINFUL MUSCULOSKELETAL SYNDROMES.
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Carbamates; Carisoprodol; Chlorphenesin; Fibromy | 1964 |
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Carbamates; Diarrhea; Drug Administration Schedule; Drug Co | 2006 |
Combined pyrethroid and carbamate 'two-in-one' treated mosquito nets: field efficacy against pyrethroid-resistant Anopheles gambiae and Culex quinquefasciatus.
Topics: Animals; Anopheles; Beds; Carbamates; Culex; Headache; Humans; Insecticides; Mosquito Control; Nitri | 2001 |